Pharma BD Deal Intelligence
A bust within six months: Incyte paid $750 million for Escient's two first-in-class MRGPR antagonists, only to discontinue EP547 after Phase 2 data failed and pause EP262 enrollment over preclinical toxicology findings by November 2024.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Incyte will pay $750 million to acquire Escient Pharmaceuticals, bringing aboard two experimental oral drugs aimed at mast-cell-driven inflammatory disease.…
Incyte said on Tuesday it would buy privately held Escient Pharmaceuticals in an all-cash deal valued at $750 million to add two experimental treatments for…
Incyte announced plans to acquire Escient Pharmaceuticals for $750 million plus net cash at close, gaining two first-in-class oral Mas-related…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Incyte (Nasdaq: INCY) acquired Escient Pharmaceuticals for $750 million plus Escient's net cash at close, announced April 23, 2024 and completed May 30, 2024. The deal brought Incyte two first-in-class oral Mas-related G protein-coupled receptor (MRGPR) antagonists: EP262 (MRGPRX2; INCB000262) for chronic urticaria and atopic dermatitis, and EP547 (MRGPRX4; INCB000547) for cholestatic and uremic pruritus -- anchoring Incyte's Inflammation & Autoimmunity pipeline. POST-CLOSE OUTCOME: on November 18, 2024, roughly six months after closing, Incyte announced both acquired lead programs had stalled. It discontinued EP547/MRGPRX4 in cholestatic pruritus after Phase 2 data did not support further development (an efficacy failure), and paused enrollment in the Phase 2 CALM-CSU study of EP262/MRGPRX2 in chronic spontaneous urticaria following in vivo preclinical toxicology findings, electing to work with the FDA on next steps while data from completed proof-of-concept studies and potential back-up molecules inform future development. The $750M outlay was upfront cash, so the impairment of both dealt-for assets materially weakened the near-term value of the acquisition.
1 US cases/yr · $4.0B Xolair 2023 global sales ($4.0B+, Novartis/Roche) as proxy for anti-IgE/CSU biologics market · ~40-50% Share of CSU patients inadequately controlled on second-generation H1 antihistamines, requiring biologic escalation
Chronic spontaneous urticaria (CSU) affects approximately 1.5-3 million US adults (~0.5-1% lifetime prevalence), characterized by recurrent itchy hives and angioedema lasting >=6 weeks without identifiable trigger. Standard-of-care second-generation H1 antihistamines fail to control symptoms in roughly 40-50% of patients, who are then escalated to omalizumab (Genentech/Novartis Xolair, anti-IgE mAb) or dupilumab (Sanofi/Regeneron Dupixent). Atopic dermatitis affects approximately 16.5 million US adults and 9.6 million US children, with moderate-to-severe disease in roughly 40% of adults, driving a large biologics-escalation market. Cholestatic pruritus in primary biliary cholangitis (PBC, ~100,000 US patients) and uremic pruritus in chronic kidney disease/dialysis (~500,000+ US patients on dialysis) represent high-unmet-need pruritus indications where itch is poorly controlled by existing agents. The MRGPRX2 receptor is a mast-cell-specific G-protein-coupled receptor that triggers IgE-independent degranulation in response to endogenous peptides (substance P, LL-37), drugs (quinolones, neuromuscular blockers), and inflammatory mediators - a pathway not addressed by anti-IgE or anti-IL-4Ra therapies. MRGPRX4 is a sensory-neuron GPCR implicated in bile-acid-driven cholestatic itch.
The CSU and chronic pruritus competitive landscape is anchored by injectable biologics: omalizumab (Genentech/Novartis Xolair, anti-IgE, $4B+ global sales) is the only FDA-approved CSU biologic, with dupilumab (Sanofi/Regeneron Dupixent, anti-IL-4Ra) approved for CSU in April 2025 and dominating atopic dermatitis. Emerging CSU entrants include Celldex Therapeutics' barzolvolimab (anti-KIT mAb, Phase 3), Novartis' remibrutinib (BTK inhibitor, Phase 3), and Sanofi/Blueprint's rilzabrutinib (BTK inhibitor, Phase 3 in CSU). Escient's EP262 (MRGPRX2 antagonist) is first-in-class oral, potentially offering an oral alternative to injectable biologics across CSU, atopic dermatitis, and drug-induced mast-cell activation. EP547 (MRGPRX4 antagonist) targets cholestatic/uremic pruritus where linerixibat (GSK IBAT inhibitor, Phase 3 PBC), odevixibat (Ipsen Bylvay, approved PFIC), and difelikefalin (Cara/Vifor Korsuva, approved uremic pruritus) compete. Incyte's JAK/itch dermatology franchise (Opzelura ruxolitinib cream) gains an oral systemic complement with EP262.
Incyte closed its acquisition of Escient Pharmaceuticals for $750 million plus net cash, gaining oral MRGPR antagonists EP262 (MRGPRX2) and EP547 (MRGPRX4).
Incyte discontinued development of MRGPRX4 (INCB000547/EP547) in cholestatic pruritus after Phase 2 data did not support further development, and paused enrollment in the Phase 2 chronic spontaneous urticaria study of MRGPRX2 (INCB000262/EP262) following in vivo preclinical toxicology findings. Both lead assets from the Escient acquisition were impaired within ~6 months of close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Incyte Corporation / Escient Pharmaceuticals Inc. (this deal) | 2024 | $750M | — |
| Incyte Corporation / MacroGenics, Inc. | 2017 | $900M | 69 |
| Incyte Corporation / Vega Therapeutics, Inc. | 2026 | $2.0B | 68 |
| Incyte Corporation / Halozyme Therapeutics, Inc. | 2026 | — | 60 |
| Incyte Corporation / Merus N.V. | 2017 | $3.0B | 35 |
| Incyte Corporation / Genesis Molecular AI, Inc. | 2026 | $1.0B | — |
| Incyte Corporation / Calithera Biosciences, Inc. | 2017 | $803M | — |
← Browse all deals · How we score deals
More: 2024 deals · Incyte Corporation deals · Dermatology deals